Eradication of HIV from CNS Reservoirs: Implications for Therapeutics Grant Program
Page 2

b) Basic research that will determine the mechanisms involved in temporal establishment, maintenance, and resurgence of CNS-based HIV-1 reservoirs in relation to the effects and timing of HAART, viral expression, and viral evolution within the patient's brain.

c) The creation of several physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of efficient HAART management.

d) Drug screening of potential agents that go beyond the blood-brain barrier and eliminate latent or other sources of residual virus within the CNS.

e) Design of therapeutic strategies aimed towards the eradication of HIV-1 from the CNS.

The funding agencies are set to administer funds in the amount of $2 million to support the initiatives of the program.

The institutions and organizations who will be considered eligible to submit an application under this program are the following:

a) Higher Education Institutions

b) Hispanic-serving Institutions and Historically Black Colleges and Universities (HBCUs)

c) Nonprofit organizations other than institutions of higher education

d) For-Profit Organizations such as Small Businesses

e) State Governments, County Governments, City or Township Governments, and Special District Governments

f) Independent School Districts

g) Public Housing Authorities

h) Faith-based or Community-based Organizations, and Regional Organizations.

Eradication of HIV from CNS Reservoirs: Implications for Therapeutics Grant Program
  Back to Page 1

About The Author Michael Saunders is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. He also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

Small Business Innovation Research Phase IIB Bridge Awards
In line with this mission, the NIH has recently constituted the Small Business Innovation Research Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization Program.

---

Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program
In keeping with this mission, the National Institutes of Health has partnered with the Canadian Institutes of Health Research (CIHR), the National Heart, Lung, and Blood Institute (NHLBI), and the Institute of Circulatory and Respiratory Health (ICRH) to establish the Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program.

---